Anti-inflammatory drugs reduce the risk of Alzheimer's disease but fail to slow its progression. Studying the expression of prostaglandin E2 synthases downstream of cyclooxygenase-2 is important. Here, the expression patterns of cytosolic prostaglandin E 2 synthases, an immediate prostaglandin E2 source was investigated. Sections taken from the middle frontal gyrus of brains of 10 patients with Alzheimer's and 5 age-matched controls were examined by immunostaining for the presence of the synthases. Immunofluorescence analysis of control brains showed that cytosolic prostaglandin E2 synthases co-localize with microglia, neurons, and endothelium markers, but not with astrocytes or smooth muscle cells. Immunohistochemical staining for the synthases was positive in the pyramidal neurons of controls but barely detectable in the brain of Alzheimer's patients. These findings revealed that cytosolic prostaglandin E2 synthases is found in microglia, neurons, and endothelium of control human middle frontal gyrus and that its levels decrease in pyramidal cells of Alzheimer's disease brains.
Thornton E., Vink R., Blumbergs PC, Van Den Heuvel C.Soluble amyloid precursor protein alpha reduces neuronal injury and improves functional outcome following diffuse traumatic brain injury in rats . Brain Res. 2006;1094:38-46.
2.
Griffin WS, Liu L., Li Y., Mrak RE, Barger SWInterleukin-1 mediates Alzheimer and Lewy body pathologies. J Neuroinflammation. 2006;3:5.
3.
Echeverria V. , Clerman A., Doré S.Stimulation of PGE2 receptors EP2 and EP4 protects cultured neurons against oxidative stress and cell death following β-amyloid exposure. Eur J Neurosci . 2005;22:2199-2206.
4.
Tanioka T., Nakatani Y., Semmyo N., Murakami M., Kudo I.Molecular identification of cytosolic prostaglandin E2 synthase that is functionally coupled with cyclooxygenase-1 in immediate prostaglandin E2 biosynthesis. J Biol Chem. 2000;275:32775-32782.
5.
Vazquez-Tello A., Fan L., Hou X., et al. Intracellular-specific colocalization of prostaglandin E2 synthases and cyclooxygenases in the brain . Am J Physiol Regul Integr Comp Physiol. 2004;287:R1155-R1163.
6.
Online Mendelian Inheritance in Man (OMIM).Prostaglandin E synthase 3. National Center for Biotechnology Information. Available at: http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=607061. Accessed May 8, 2008.
Mirra SS, Heyman A., McKeel D., et al. The consortium to establish a registry for Alzheimer's disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991;41:479-486.
Tanaka Y., Furuyashiki T., Matsuoka T., Kitaoka S., Narumiya S.In Situ Hybridization Analyses of Cytosolic Prostaglandin E Synthase in Mouse Brains. Washington, DC: Society for Neuroscience; 2005.
11.
Hoozemans JJ , Rozemuller AJ, Janssen I., De Groot CJ, Veerhuis R., Eikelenboom P.Cyclooxygenase expression in microglia and neurons in Alzheimer's disease and control brain . Acta Neuropathol (Berl). 2001;101:2-8.
12.
Yermakova AV , O'Banion MKDownregulation of neuronal cyclooxygenase-2 expression in end stage Alzheimer's disease. Neurobiol Aging . 2001;22:823-836.
13.
Allen Brain Atlas [Internet].Allen Institute for Brain Science. Available at: http://www.brain-map.org. Accessed May 8, 2008.
14.
Maida ME, Hurley SD, Daeschner JA, Moore AH, Kerry O.'banion M. Cytosolic prostaglandin E(2) synthase (cPGES) expression is decreased in discrete cortical regions in psychiatric disease. Brain Res. 2006;1103:164-172.
15.
Sang N., Zhang J., Marcheselli V., Bazan NG, Chen C.Postsynaptically synthesized prostaglandin E2 (PGE2) modulates hippocampal synaptic transmission via a presynaptic PGE2 EP2 receptor. J Neurosci. 2005; 25:9858-9870.
16.
Hofacker A., Coste O., Nguyen HV, Marian C., Scholich K., Geisslinger G.Downregulation of cytosolic prostaglandin E2 synthase results in decreased nociceptive behavior in rats. J Neurosci. 2005;25: 9005-9009.
17.
Pickering G. , Jourdan D., Dubray C.Acute versus chronic pain treatment in Alzheimer's disease. Eur J Pain. 2006;10:379-384.
18.
Scherder E., van Manen F.Pain in Alzheimer's disease: nursing assistants' and patients' evaluations . J Adv Nurs. 2005;52:151-158.
19.
Nakatani Y. , Hokonohara Y., Kakuta S., Sudo K., Iwakura Y., Kudo I.Knockout mice lacking cPGES/p23, a constitutively expressed PGE2 synthetic enzyme, are perinatally lethal. Biochem Biophys Res Commun. 2007;362:387-392.
20.
Combrinck M. , Williams J., De Berardinis MA, et al. Levels of CSF prostaglandin E2, cognitive decline, and survival in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2006;77:85-88.
21.
Kobayashi T. , Nakatani Y., Tanioka T., et al. Regulation of cytosolic prostaglandin E synthase by phosphorylation. Biochem J. 2004;381:59-69.
22.
Greenwood JA , Scott CW, Spreen RC, Caputo CB, Johnson GVCasein kinase II preferentially phosphorylates human tau isoforms containing an amino-terminal insert. Identification of threonine 39 as the primary phosphate acceptor. J Biol Chem.1994;269:4373-4380.
23.
Masliah E., Iimoto DS, Mallory M., Albright T., Hansen L., Saitoh T.Casein kinase II alteration precedes tau accumulation in tangle formation . Am J Pathol. 1992;140:263-268.
24.
Amadoro G., Ciotti MT, Costanzi M., Cestari V., Calissano P., Canu N.NMDA receptor mediates tauinduced neurotoxicity by calpain and ERK/MAPK activation . Proc Natl Acad Sci U S A. 2006;103:2892-2897.
25.
Angenstein F., Buchner K., Staak S.Age-dependent differences in glutamate-induced phosphorylation systems in rat hippocampal slices. Hippocampus . 1999; 9:173-185.
